<DOC>
	<DOCNO>NCT00043043</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may effective prevent colorectal cancer patient history rectal polyp colorectal neoplasia . PURPOSE : Randomized phase II trial study effectiveness celecoxib prevent colorectal cancer patient history rectal polyp colorectal neoplasia .</brief_summary>
	<brief_title>Celecoxib Preventing Cancer Patients With Rectal Polyps Colorectal Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect celecoxib vs placebo number rectal aberrant crypt focus patient premalignant rectal polyp prior sporadic colorectal neoplasia . Secondary - Compare effect drug proliferation index , apoptotic index , gene expression pattern ascend descend colon tissue patient treatment . - Assess gene expression pattern normal mucosa ascend v descend colon patient refer screen , surveillance , diagnostic colonoscopy . OUTLINE : This randomize , double-blind , placebo-controlled , chemoprevention study . Patients stratify accord age ( 18 49 v 50 ) number rectal aberrant crypt focus ( 5-9 v 10 ) . All patient undergo baseline biomarker assessment full colonoscopy resect neoplasm , quantitate rectal aberrant crypt focus , biopsy rectal mucosa . Depending result biomarker assessment , patient randomize 1 2 treatment arm . Patients adenomas 5 mm great receive treatment . - Arm I : Patients receive oral celecoxib twice daily . - Arm II : Patients receive oral placebo twice daily . In arm , treatment continue 6 month absence unacceptable toxicity . All patient undergo endoscopic exam colorectum completion study . PROJECTED ACCRUAL : A total 100 patient accrue baseline biomarker assessment total 40 patient ( 20 per arm ) accrue chemoprevention study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Age 18 49 one follow colorectal abnormality : At least one adenoma least 1 cm At least 3 adenomas size least 5 rectal aberrant crypt focus ( ACFs ) Age 50 one follow colorectal abnormality : At least one adenoma least 5 mm least 5 rectal ACFs History polyp ( least 1 adenoma ) within past 5 year No history germline cancer syndrome No stage III IV colorectal cancer ( Dukes ' C D ) diagnose within past 6 month No current colorectal cancer No inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) PATIENT CHARACTERISTICS : Age See Disease Characteristics 18 Performance status Not specify Life expectancy Not specify Hematopoietic Hemoglobin great 11.5 g/dL WBC great 3,000/mm^3 Platelet count great 125,000/mm^3 No significant bleed disorder Hepatic AST ALT great 1.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Alkaline phosphatase great 1.5 time ULN No chronic acute hepatic disorder Renal Creatinine great 1.5 time ULN No chronic acute renal disorder Cardiovascular No uncontrolled hypertension No unstable angina No congestive heart failure Pulmonary No asthma No severe chronic obstructive pulmonary disease Gastrointestinal No active gastrointestinal ulcer No history peptic ulcer disease Other No prior hypersensitivity reaction NSAIDs , aspirin , sulfa drug No medical contraindication NSAID use Not pregnant nursing Negative pregnancy test Fertile female patient must use effective contraception No know allergic reaction indigo carmine No clinically significant medical condition abnormal laboratory value would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Anticipated use corticosteroid less 2 week 6 month Anticipated use mometasone le 4 week 6 month No concurrent inhale steroid 30 day study participation Radiotherapy No prior pelvic radiotherapy Surgery Not specify Other More 30 day since prior investigational drug No prior participation study No regular nonsteroidal antiinflammatory drug ( NSAID ) aspirin use ( average 3 dos per week least 3 month ) except lowdose aspirin cardiovascular disease prophylaxis No concurrent investigational drug No concurrent fluconazole lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>colorectal cancer</keyword>
</DOC>